Nasus Pharma Ltd, a clinical-stage pharmaceutical firm centered on progressive intranasal merchandise for emergency medical circumstances, has initiated its Part 2 medical research for NS002, its investigational intranasal epinephrine powder formulation. The corporate introduced the dosing of the primary participant in Canada, marking a vital step within the improvement of one other needle-free nasal spray different to conventional epinephrine auto-injectors for the emergency therapy of anaphylaxis.
The profitable initiation of this trial displays the fruits of preclinical work and a earlier medical research, which demonstrated that NS002 can obtain sooner and better absorption of epinephrine in comparison with an auto-injector. Discussing the significance of this system, Dan Teleman, CEO of Nasus Pharma, said:
The dosing of the primary participant in our Part 2 research marks a big milestone for our NS002 program and for sufferers with extreme allergy symptoms who want extra user-friendly therapy choices to handle life-threatening anaphylaxis.
The necessity for less complicated administration strategies stays excessive, as points associated to present injection-based units typically result in suboptimal affected person care. Teleman elaborated on this unmet want, noting the compliance problem related to present supply techniques: “For tens of millions affected by extreme allergy symptoms, the concern of needles and the inconvenience of carrying cumbersome autoinjectors results in poor compliance and doubtlessly life-threatening outcomes in anaphylaxis administration.” NS002 is being developed to beat these boundaries, providing a non-invasive, pocket-friendly resolution.
The Part 2 research is an open-label, fixed-sequence trial designed to robustly consider the drug candidate. The first goal is to judge the pharmacokinetic parameters (how the drug is absorbed and processed by the physique) and hemodynamic responses (results on blood circulation) of NS002. The trial will evaluate NS002 with the established market chief, EpiPen, in a cohort of fifty wholesome grownup individuals with a historical past of allergic rhinitis.
The fast, dependable supply of NS002 is enabled by Nasus’s proprietary Powder-Based mostly Intranasal (PBI) know-how. This progressive platform is designed to leverage the nasal cavity’s wealthy vascular community for fast absorption into the bloodstream. The PBI formulation makes use of uniform spherical powder particles to make sure broad dispersion and doubtlessly sooner, increased absorption charges in comparison with liquid-based nasal sprays, which may very well be important when treating acute, time-sensitive circumstances like anaphylaxis.
With the medical program now absolutely underway, Nasus Pharma is targeted on advancing the product as shortly as doable. The CEO confirmed the event pipeline is “shifting ahead at full velocity, executing the NS002 improvement program as deliberate, and positioning the Firm for its subsequent stage of development.” The corporate anticipates reporting key interim outcomes from this pivotal Part 2 trial within the first quarter of 2026, providing a transparent timeline for the development of this promising needle-free therapy choice.
